Condition: Cancer · Melanoma Stage III · Melanoma Stage IV · Sponsor: Krystal Biotech, Inc.
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Opdualag to subjects with unresectable or metastatic melanoma. Subjects in dose escalation (Cohorts 1 through 3) and dose expansion (Cohort 4) will receive intratumoral injections of KB707 approximately every three weeks. Cohorts 1 through 4 are closed to new enrollment. Dose expansion Cohort 5 and Cohort 6 will evaluate subjects with advanced melanoma. Subjects in Cohort 5 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Opdualag (dosed every q4w per prescribing information). Subjects in Cohort 6 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Keytruda (dosed every q6w per prescribing information). All subjects will be treated until disease progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.
This description comes directly from the study's public registry record.
David Chien, MD · 412-586-5830 · dchien@krystalbio.com
Brittani Agostini, RN, CCRC · 412-586-5830 · bagostini@krystalbio.com
Always discuss trial participation with your own doctor first.
| UCLA Health | Los Angeles, California, United States | Recruiting |
| Mission Dermatology Center | Rancho Santa Margarita, California, United States | Recruiting |
| BRCR Global | Weston, Florida, United States | Recruiting |
| IU Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| Henry Ford Cancer Institute | Detroit, Michigan, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Morristown Medical Center / Atlantic Health System | Morristown, New Jersey, United States | Recruiting |
| Weill Cornell Medicine-New York-Presbyterian Hospital | New York, New York, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05970497